Cell-therapy company Vericel (VCEL) delivered strong third-quarter earnings driven by success from MACI, a cartilage cell implant that repairs joints, and Epicel, which …
BTIG’s Ryan Zimmerman shares his key takeaways from VCEL’s Analyst Day- with a confident verdict.
BTIG’s Ryan Zimmerman now spotlights 18% in return potential for VCEL shares on back of an impressive fourth quarter performance.
Biopharmaceutical company Vericel Corp (NASDAQ:VCEL) reported record revenues and improved net income for the 2017 fourth quarter and full year, sending shares rising nearly 8% in …
BTIG feels confident in Vericel core business as ixmyelocel-T’s future became uncertain.
Highlights from investor meetings with Vericel management.
Shares of Vericel Corp (NASDAQ:VCEL) are soaring nealy 67% as of 8:30 a.m.
